Zacks Small Cap Research – MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial… – Go Health Pro

Zacks Small Cap Research – MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial… – Go Health Pro

By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The trial had two parts: … Read more

Catastrophe bonds rarely more compelling on a relative basis: Icosa – Go Health Pro

Catastrophe bonds rarely more compelling on a relative basis: Icosa – Go Health Pro

On a relative basis, catastrophe bonds have rarely presented a more compelling investment opportunity than today, as despite spreads having tightened somewhat the cat bond asset class diversification offering can be at its strongest when other assets like equities are overvalued, fund manager Icosa Investments has said.Previously, the investment manager has explained that with catastrophe … Read more

x